ABCG2 and breast carcinoma: ABCG2 was originally cloned from breast tumor cell lines and placental tissue in 1998 [158,159,160] and its isolation from a multidrug resistant breast cancer (Mcf7-derived) cell line led to its latest term as the ‘breast cancer resistance protein.’ MDR is the most frequent phenomenon associated with the failure of chemotherapy.